Quantcast

Health Robotics Announces i.v.STATION(R) ONCO, a Next Generation Robot for Intravenous Cancer Therapy

March 7, 2011

BOZEN, Sud-Tirol, Italy, March 7, 2011 /PRNewswire/ — Health Robotics
today announced the completion of its initial research, development, and
factory-testing activities for its next-generation Cancer Therapy Robot,
i.v.STATION ONCO, and its unveiling at the European Association of Hospital
Pharmacists (EAHP) in Vienna on 1 April 2011, including its new overpowering
features: four times faster, five times smaller, and three times less
expensive than some of the other Sterile Compounding Robotic devices in the
market.

“I do believe that it is now the right time for Generale de Sante to move
forward to Robotics Automation for our strategic Oncology Sterile Compounding
workflow processes. I’m very proud to partner with Health Robotics in the
hospital testing process of its new i.v.STATION ONCO” asserted Filippo
Monteleone
, Generale de Sante’s Managing Director.

i.v.STATION ONCO is scheduled to be released to Beta-Test and Early
Adopter Program status in approximately 6 months to Generale de Sante in
Paris, Bolzano General Hospital in Italy [working side-by-side and in synergy
with CytoCare], and Health Robotics South East Asia’s own compounding center
in Kuala Lumpur, Malaysia. Worldwide general availability for i.v.STATION
ONCO is originally targeted for 1Q2012, including Class II medical device
certification for the United States of America.

“It is indeed a key milestone for Health Robotics to enter the French
healthcare market, and an honor to partner with Generale de Sante, France’s
top private hospital group. With i.v.STATION ONCO, we continue to
unquestionably lead Global Oncology Automation by introducing our 3rd
automated solution for Hazardous Sterile Compounding before any of our direct
competitors bring their 1st proven solution to the market [some of which were
announced over 20 years ago[1]. i.v.STATION ONCO symbolizes the next pillar
in Health Robotics’ strategy to build a cost-effective, redundant, and
patient-safe network of devices that address the flexibility, throughput,
high-availability, and protection required within Cancer Therapy” stated
Gaspar DeViedma, Health Robotics’ Executive Vice President.

i.v.STATION ONCO represents a complementary offering to other Health
Robotics’ solutions for sterile compounding of Intravenous Cancer Therapy:
CytoCare and i.v.SOFT Assist. Engineered as an evolution and blending of some
of the fully-tested and globally-embraced technologies embedded within
i.v.STATION and CytoCare, i.v.STATION ONCO automatically compounds, caps, and
labels commercially-available soft plastic bags and syringes from 8 different
brands and 10 different sizes within an ISO-5 environment on negative
pressure. i.v.STATION ONCO however does not support sterile compounding with
ampoules, plastic or glass bottles, CSTDs, unusually small vials, and
elastomeric infusors, which Health Robotics’ customers will need to continue
to compound with market-leading CytoCare and/or i.v.SOFT Assist solutions.

“We look forward to repeat the rigorous SafeChemo scientific validation
we undertook with CytoCare in 2008, including world-leading and peer-reviewed
sterility and cross-contamination tests with i.v.STATION ONCO, and to divide
our Oncology Therapy workload with CytoCare, each robot being utilized for a
particular purpose and need” stated Dr. Pietro Paluselli, Director of
Pharmacy at Bolzano General Hospital.

About Generale de Sante:

Founded in 1987 and listed by Euronext since 2001, Generale de Sante is
the leading group in the private hospital care sector in France with 21,500
employees, including 7,000 nurses and 4,100 assistant nurses in 110 hospitals
and clinics. With 5,500 physicians, it represents the leading independent
medical community in France. Generale de Sante provides a complete range of
patient care services spanning: acute care, oncology, sub-acute care and
rehabilitation, mental health and homecare. It has developed an original
healthcare offering, combining medical excellence, organizational efficiency
and a human touch; it provides an all-in-one service with an
individually-adapted patient support package, before, during and after
hospitalization, taking into consideration all of its patients’ needs.

About Health Robotics:

Health Robotics is the undisputed global leading supplier of
life-critical intravenous medication robots, providing over 175 hospital
installations in 5 continents with robotics technology and software
automation solutions deployed utilizing virtual high-availability technology.
Its world-leading solutions CytoCare(R) and i.v.STATION(R) ONCO [hazardous
IVs], i.v.STATION(R) [non-hazardous IVs], i.v.SOFT(R) [workflow engine for
manual compounding], MEDarchiver(R) [life-critical clinical information
system], and TPNstation(TM) [totally-automated parenteral nutrition] have and
will greatly contribute to ease hospitals’ growing pressures to improve
patient safety, increase throughput and contain costs. Through the effective
and efficient production of sterile, accurate, tamper-evident and
ready-to-administer IVs, Health Robotics’ solutions help hospitals eliminate
life-threatening drug and diluent exchange errors, decrease other medical
mistakes and sterility risks, work more efficiently, reduce waste and
controlled substances’ diversion, and diminish the gap between rising patient
volume/acuity and scarce medical, nursing, and pharmacy staff. For more
information, please visit: http://www.health-robotics.com

    [1] Am J Hosp Pharm 46(11): 2286-93-1989

    For additional information, please contact:
    Claudia Flaim, Marketing Coordinator
    flaim@health-robotics.com
    Phone: +39-0471-200-372

SOURCE Health Robotics


Source: newswire



comments powered by Disqus